Retatrutide, a new dual agonist of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) receptor , is exhibiting promising results in preliminary patient assessments . Recent research https://bookmarkpressure.com/story21284202/retatrutide-emerging-investigations-and-potential-medical-roles